Newbridge Financial Services Group Inc. Takes $36,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 300 shares of the biotechnology company’s stock, valued at approximately $36,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its stake in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. raised its stake in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank raised its stake in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Sarepta Therapeutics during the third quarter valued at about $59,000. 86.68% of the stock is currently owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. Robert W. Baird dropped their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Down 2.7 %

Shares of NASDAQ SRPT opened at $109.68 on Wednesday. The stock has a market cap of $10.48 billion, a price-to-earnings ratio of 87.74 and a beta of 0.75. The business has a 50 day simple moving average of $120.49 and a 200 day simple moving average of $125.33. Sarepta Therapeutics, Inc. has a 52 week low of $102.15 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.